A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : CA-125 has been found to be high in almost all the patients with ascites. In this study, we tried to determine cut-off values of CA-125 in serum and ascitic fluid levels in order to discriminate non-ovarian malignancies, ovarian carcinomas and benign diseases. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : A total of 119 patients were included in the study. The patients were divided into three groups: non-ovarian malignancies, ovarian carcinoma and benign diseases. Serum and ascitic fluid CA-125 levels were measured by electrochemiluminescence immunoassay, 'ECLIA' method. In determining the discriminitive ability of CA-125 levels between the groups, receiver operating characteristic (ROC) analysis was performed. R Re es su ul lt ts s: : A total of 119 patients were included in the study: 55 males and 64 females. Of patients, 53 had non-ovarian malignancy, 19 had ovarian carcinoma and 47 had benign diseases. Serum and ascitic fluid CA-125 levels were high in all of the three groups. When cut-off value of ascitic CA-125 was taken as 174 U/mL, the sensitivity and specificity were found to be 69.2% and 25.5%, respectively; however, when the value was accepted as 796.5 U/mL, these rates were observed as 30.8% and 80.9% respectively. In the discrimination between ovarian carcinoma and benign diseases, when the cut-off value of ascitic CA-125 was considered as 411 U/mL, the sensitivity and specificity were obtained as 94.7% and 63.8% respectively. When the value was taken as 971.9 U/mL, the sensitivity and specificity rates were 57.9% and 78.7% respectively. C Co on nc cl lu us si io on n: : In discriminating between malign and benign ascites, ascitic CA-125 levels rather than serum values are of significance, and it can be suggested that malignancy should be persistently searched when the value is over 1000 U/mL. K Ke ey y W Wo or rd ds s: : CA-125 antigen; ascites Ö ÖZ ZE ET T A Am ma aç ç: : Asitli hastaların neredeyse tümünde CA-125 yüksekliği görülmektedir. CA-125 serum ve asit düzeylerinin over-dışı malign, over adenokarsinomu ve benign hastalıkları ayırmada cut-off değerlerini belirlemeye çalıştık. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışmaya toplam 119 asitli hasta dahil edildi. Hastalar over-dışı malign, over carsinomu ve benign hastalıklar şeklinde gruplandırıldı. Serum ve asit mayi CA-125 düzeyleri ölçüldü. CA-125 electrochemiluminescence immunoassay ''ECLIA'' metodu kullanılarak çalışıldı. CA-125 düzeyinin grupları birbirinden ayırt edebilme becerisini belirlemede "receiver operating characteristic (ROC)" analizi kullanıldı. B Bu ul lg gu ul la ar r: : Çalışmaya 64 bayan 55 erkek toplam 119 hasta dahil edildi. Elli üçü over-dışı malign, 19'u over adenokarsinomu ve 47'si benign hastalardı. Serum ve asit mayi CA-125 düzeyleri her üç grupta da yüksekti. Duyarlılık ve özgüllük over-dışı malign ve benign ayırımında asit CA-125 cut-off değeri 174.5 U/mL iken sırasıyla %69.2 ve %25.5; değer 796.5 U/mL iken sırasıyla %30.8 ve %80.9 idi. Over adenokarsinomu ve benign ayırımında cut-off değer 411 U/mL iken duyarlılık ve özgüllük sırasıyla %94.7 ve %63.8; değer %71.9 U/mL iken sırasıyla %57.9 ve %78.7 idi. S So on nu uç ç: : Malign ve benign asit ayırımında serumdan ziyade asit mayi CA-125 düzeylerinin anlamlı olduğu ve 1000 U/mL'in üstündeki değerlerde malignitenin ısrarla aranması önerilebilir. 
ar bohy dra te an ti gen-125 (CA-125) is a high mo le cu lar we ight glycop ro te in de tec ted by the OC125 mo noc lo nal an ti body, which was first des cri bed by Bast et al. in 1981. 1 CA-125 is wi dely used for the di ag no sis, mo ni to ring and recur ren ce in pa ti ents with ova ri an can cers. 2 Whi le it only in cre a ses in ap pro xi ma tely 50% of sta ge 1 pa ti ents with epit he li al ova ri an can cers, it in cre ases in 75-90% of tho se with ad van ced di se a se. 3 CA-125 is not en ti rely spe ci fic for ova ri an car ci no ma. 4 Furt her mo re, it has al so be en re por ted to in cre a se in be nign and physi o lo gic con di ti ons such as mens tru a ti on, preg nancy, chro nic re nal fa i lu re, au toim mu ne di se a se, pan cre a ti tis, li ver cirr ho sis and inf lam ma ti on of pe ri to ne um, ple u ra and pe ri car dium. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] As ci tes is produced ap pro xi ma tely 80% by chro nic pa rench ymal li ver di se a se, and ap pro xima tely 10% by ma lig nancy. 16 The most be nign rea son of high le vel of CA-125 is li ver cirr ho sis comp li ca ted with as ci tes.
14 Pe ri to ne al me sot he li al cells are ac cep ted as the so ur ce of CA-125 in condi ti ons as so ci a ted with as ci tes. 17 CA-125 has be en fo und to be high in ne arly all of the pa ti ents with as ci tes. 10, 18 The re fo re, CA-125 in cre a ses in both malig nant and be nign diseases ca u sing as ci tes. So, it is sug ges ted that it has li mi ted di ag nos tic va lu e as a mar ker of can cer. In ad di ti on, it is still con tro versi al whet her it is an ap prop ri a te tu mor mar ker. 12, 19 We ai med to in ves ti ga te the ro le of CA 125 levels in se rum and as ci tes in dif fe ren ti al di ag no sis of ova ri an and non-ova ri an ma lig nan ci es and be nign con di ti ons.
MA TE RI AL AND MET HODS

PA TI ENTS AND STUDY DE SIGN
A to tal of 119 adult con se cu ti ve pa ti ents with as cites we re en rol led for this study. The ca ses we re collec ted from Gas tro en te ro logy, Me di cal On co logy and Gyne co logy de part ments of Dic le Uni ver sity Hos pi tal bet we en March 2006 and Ju ne 2008. The study was car ri ed out in ac cor dan ce with the princip les sta ted in the Dec la ra ti on of Hel sin ki, and signed in for med con sents were ob ta i ned from all pa ti ents pri or to inc lu si on in the study. As this study was per for med as part of ro u ti ne cli ni cal prac ti ce, et hics com mit te e ap pro val was not re qui red. All da ta and con tact in for ma ti on for the se pati ents ha ve be en fi led and the pa ti ents can be con tac ted at any ti me. Ro u ti ne he ma to lo gi cal, bi oc he mi cal and ra di o lo gi cal in ves ti ga ti ons we re perfor med. Be si des, blo od and as ci tes samp les we re ob ta i ned from the pa ti ents and pro ces sed for CA 125 by using elec troc he mi lu mi nes cen ce im mu noas say ''ECLI A'' met hod (Roc he Mo du lar Analy tics E170, Co bas, Roc he Di ag nos tics GmbH Mann heim, Ger many).
The inc lu si on cri te ri a for this study was the pre sen ce of cli ni cally de tec tab le as ci tes, age gre ater than 15 ye ars and not re ce i ving any t reat ment for as ci tes. The pa ti ents with ma lig nancy who rece i ved any tre at ment for the di se a se we re exc lu ded in or der to avo id a pos sib le ne ga ti ve con tri bu ti on.
A to tal of 119 pa ti ents we re di vi ded in to three gro ups ba sed on the di ag no sis.
Gro up 1 con sis ted of 53 pa ti ents with nonova ri an ma lig nancies. Di ag no ses of ma lig nancy were ma de by po si ti ve his to pat ho lo gi cal eva lu a ti on in the spe ci mens ob ta i ned by la pa ros copy, en dos copy or la pa ro tomy and a po si ti ve as ci tic flu id cyto lo gical exa mi na ti on. Di ag nos tic dis tri bu ti on of gro up 1 was as fol lows: 16 we re gas tric car ci no ma, 10 were co lon car ci no ma, nine we re ma lign me sot he li oma, nine we re he pa to cel lu lar car ci no ma, five we re pan cre as ade no car ci no mas and four we re nonHodg kin's lympho ma.
Gro up 2 con sis ted of 19 pa ti ents with his to logi cally con fir med ova ri an can cer and as ci tes. All pa ti ents with ova ri an car ci no ma had ad van ced stage ac cor ding to FI GO clas si fi ca ti on.
Gro up 3 con sis ted of 47 pa ti ents with be nign con di ti ons ca u sing as ci tes. Dis tri bu ti on of Gro up 3 was as fol low: 37 we re li ver cirr ho sis (11 with spon ta ne o us bac te ri al pe ri to ni tis), eight we re tuber cu lo us pe ri to ni tis, one was pan cre a tic as ci tes, and one was gra nu lo ma to us pe ri to ni tis. In the Group 3, ma lig nancy was exc lu ded by his tory, exa mina ti on and re le vant in ves ti ga ti ons. Ul tra so und exa mi na ti on and/or CT scan re ve a led li ver in volve ment by ma lig nancy.
Tüzün ve ark. Gastroenterohepatoloji
STA TIS TI CAL ANALY SIS
The me an va lu es of the va ri ab les we re cal cu la ted. Da ta we re analy zed for the dif fe ren ces among the gro ups by using one-way ANO VA or stu dent's t test. Re ce i ver ope ra ting cha rac te ris tic analy sis (ROC) and are a un der cur ves (AUCs) we re used to de ter mi ne the dis cri mi na ti ve abi lity of as ci tic fluid and se rum CA-125. Per fect dis cri mi na ti on has a ROC plot pas sing thro ugh the up per left cor ner (100% sen si ti vity, 100% spe ci fi city). The clo ser the ROC plot to the up per left cor ner, the hig her the ove rall ac cu racy of the test (AUC: 0.9-1 in di ca ting ex cel lent; 0.8-0.9 very go od; 0.7-0.8 go od; 0.6-0.7 ave ra ge; 0.5-0.6 po or). P < 0.05 was con si de red as sta tis ti cally sig ni fi cant. The sen si ti vity and spe ci ficity of as ci tic flu id and se rum CA-125, and cut-off po ints we re cal cu la ted. Cor re la ti ons we re cal cu lated using Pe ar son's cor re la ti on co ef fi ci ent met hod. Sta tis ti cal analy ses we re car ri ed out using the statis ti cal pac ka ges for SPSS 15.0 for Win dows (SPSS, Inc., Chi ca go, IL, USA).
RE SULTS
Of 119 pa ti ents pre sen ted with as ci tes, the re we re 64 fe ma les and 55 ma les. Pa ti ents' cha rac te ris tics are shown in Tab le 1. The dis tri bu ti on of ca ses on the ba sis of gro ups and me an va lu es of se rum and as ci tic flu id CA-125 are shown in Tab le 2.
A sig ni fi cant po si ti ve cor re la ti on was fo und in the cor re la ti on analy sis bet we en the se rum and asci tic flu id CA-125 le vels (cor re la ti on co ef fi ci ent 0.518, p<0.001).
The me an va lu e of the se rum le vels of CA 125 (sCA 125) we re in a rank order from the hig hest to the lo west in non-ova ri an ma lig nancy, ova ri an car ci no ma and be nign gro up, res pec ti vely. Ne verthe less, the re was no sig ni fi cant dif fe ren ce among the gro ups (p= 0.135).
As ci tic flu id le vels of CA-125 (aCA-125) we re hig hest in ova ri an car ci no ma. The re we re sig ni ficant dif fe ren ces bet we en ova ri an car ci no ma and the ot her gro ups (p= 0.003, <0.001 non-ova ri an malig nant and be nign gro ups res pec ti vely). Mo re o ver, ascitic CA-125 (aCA-125) le vels of Gro up 1 we re sig ni fi cantly hig her than tho se of Gro up 3 (p= 0.048) Tab le 2 gi ves the com pa ri sons of aCA-125 and serum CA-125 (sCA-125) le vels bet we en the gro ups.
Fi gu re 1-A shows the ROC cur ve for dis cri mina ti ve abi lity of aCA-125 and sCA-125 in pa ti ents with non-ova ri an can cers and be nign disorders. Ac cor ding to the re sults of ROC cur ve and AUC va lue, dis cri mi na ti ve abi lity of se rum CA-125 was not sta tis ti cally sig ni fi cant (p= 0.596) but as ci tic fluid CA-125 was sig ni fi cant (p= 0.09). When cut-off va lu e of aCA-125 was ac cep ted as 174.5 U/ml, the sen si ti vity and spe ci fi city we re 69.2% and 25.5%, res pec ti vely. When cut-off va lu e of aCA-125 was ta ken as 353 U/ml, the sen si ti vity and spe ci fi city we re 50% and 51.1%, res pec ti vely. Ho we ver, when cut-off va lu e of aCA-125 was ac cep ted as 796.5 U/ml, the sen si ti vity and spe ci fi city we re de ter mined as 30.8% and 80.9%, res pec ti vely.
Fi gu re 1-B shows the ROC cur ve for dis crimi na ti ve abi lity of aCA-125 and sCA-125 in pa tients with ova ri an car ci no ma and be nign pa ti ents. Ac cor ding to the re sults of ROC cur ve and AUC va lu e, dis cri mi na ti ve abi lity of sCA-125 was not sta tis ti cally sig ni fi cant (p=0.318), ho we ver, aCA125 was sig ni fi cant (p<0.001). When cut-off va lu e of aCA-125 was ac cep ted as 411.75 U/ml, the sen si ti vity and spe ci fi city we re fo und as 94.7% and 63.8%, res pec ti vely. When cut-off va lu e of aCA-125 was ac cep ted as 971.9 U/ml, the sen si ti vity and spe ci fi city we re found as 57.9% and 78.7%, respec ti vely.
The pos sib le re la ti ons hip bet we en se rum and as ci tic flu id CA-125 le vels and le vel of li ver cirrho sis was analy zed ac cor ding to Child-Pugh sta ge.
The re we re no sta tis ti cally significant relationship bet we en the le vel of CA-125 and the sta ge of li ver cirr ho sis (p= 0.781, 0.867, 0.934 for Child-Pugh stage A,B,C res pec ti vely).
In be nign gro up, the re we re 37 pa ti ents with li ver cirr ho sis, and 11 pa ti ents with spon ta ne o us bac te ri al pe ri to ni tis. The re we re no dif fe ren ces bet we en se rum and as ce tic flu id CA-125 le vels (p= 0.853, 0.321 res pec ti vely) ac cor ding to the pre sence or ab sen ce of spon ta ne o us bac te ri al pe ri to nitis.
DIS CUS SI ON
An ideal marker that can be used to diagnose cancer must be sec re ted in to the pa ti ents' se ra only in ca se of the presen ce of a spe ci fic can cer, and ha ve ac cep tab le sen si ti vity to de tect early sta ge of cancer; it al so must be highly spe ci fic to avo id con fusi on with be nign di se a ses.
CA-125, which is the most use ful mar ker, has be en most ex ten si vely stu di ed for ova ri an car ci noma, es pe ci ally in mo ni to ring pa ti ents with this di se a se. Li ke many ot her tu mor mar kers, CA-125 is not a tu mor spe ci fic an ti gen, so it has li mi ted speci fi city when used alo ne. CA-125 level may al so incre a se in the pre sen ce of ot her can cers such as pe ri to nel car ci na ma to sis, pan cre a tic, bre ast, bladder, li ver, lung can cers 4, 5 as well as be nign di se a ses such as li ver cirr ho sis, di ver ti cu li tis, le i om yo ma, en do met ri o sis, be nign ova ri an cyst, tu bo-ova ri an abs cess, re nal di se a se [8] [9] [10] [11] 14, 20 and physi o lo gic con diti ons such as preg nancy and mens tru a ti on. 6, 7, 21 The ori gin of CA-125 still re ma ins unc le ar, and ova ri an, pe ri to ne al, ple u ral, en do met ri al and am ni o tic cells ha ve be en de mons tra ted to pro du ce and sec re te it. 22 By using tis su e cul tu re, Ko ba yas hi sho wed that the eu to pic and the he te ro to pic en domet ri um co uld pro du ce CA-125. 23 Si mi larly, the re is al so anot her study re por ting that pe ri to ne um has pro du ced CA-125 in vi vo. 22 High le vel of CA-125 in be nign con di ti ons is mostly en co un te red in li ver cirr ho sis comp li ca ted with as ci tes. Col la zos et al. sug ges ted that se rum CA-125 had ex cel lent sen si ti vity, spe ci fi city, ef fici ency, pre dic ti ve va lu es and li ke li ho od ra ti os to Tüzün ve ark. Gastroenterohepatoloji de tect as ci tes in pa ti ents with non-ne op las tic li ver di se a ses. 15 The re are se ve ral da ta abo ut the in cre ase of CA-125 in li ver cirr ho sis es pe ci ally with as cites. 5, 11, 12, 14 Mo li na et al. emp ha si zed that sCA-125 le vels in cre a sed in in fec ti ons of the as ci tic flu id and dec re a sed af ter pa ra cen te sis, thus sug ges ting that the as ci tic flu id was a re ser vo ir for the an ti gen, which is synthe si zed by the pe ri to ne um. 14 In the pre sent study, se rum CA-125 le vels we re be low 35 U/ml in only four pa ti ents (%3.36), but as ci tic fluid le vels of CA-125 we re hig her than 35 U/ml in all of the pa ti ents. We fo und a po si ti ve cor re la ti on bet we en se rum and as ci tic flu id le vels of CA-125, however as ci tic flu id le vels we re hig her than serum le vels. The re fo re, the se fin dings may sup port that the an ti gen is me sot he li al rat her than tu mo ral ori gin.
It was sug ges ted ear li er that in cre a se of se rum CA-125 le vels in li ver cirr ho sis were clo sely cor rela ted with as ci tes rat her than a he pa tic di sor der.
12,24
We co uld not find any cor re la ti on bet we en se rum and as ci tic flu id CA-125 le vels and Child-Pugh score of pa ti ents with li ver cirr ho sis. We al so co uld not de tect any cor re la ti on bet we en pa ti ent with cirr ho sis in terms of pre sen ce and ab sen ce of sponta ne o us bac te ri al pe ri to ni tis. Pe ri to ne al inf lam mati on with bac te ri al agent is a sig ni fi cant sti mu la tor of me sot he li al cells. Thus, this out co me has con fused us. We tho ught that it co uld be du e to small num ber of our pa ti ents.
CA125 is well es tab lis hed as a tu mor mar ker for epit he li al ova ri an can cer, and has an im por tant ro le in di ag no sis. In a study in which the ro le of CA-125 was dis cus sed, it was re por ted that the sensi ti vity of CA125 for ova ri an can cer in fe ma le pati ents was 88.6%, however the spe ci fi city was only 72.0%. 3 The authors sug ges ted that when the CA-125 re sults over 1000 kU/lit re we re detected, the spe ci fi city of CA-125 in cre a sed to 99.1%. 3 To pa lak et al. re por ted that CA-125 le vel in ova ri an car cino ma with as ci tes was six ti mes hig her than tho se with ova ri an car ci no ma wit ho ut as ci tes.
12 They could not find any cor re la ti on bet we en ova ri an mass vo lu me and CA-125 le vels, thus, they sug ges ted that high se rum le vels are clo sely cor re la ted with exis ten ce of as ci tes. Le Thi Hu ong et al. re por ted that a CA-125 level hig her than 1,000 U/ml was always du e to the pre sen ce of can cer; lo wer levels must be in ter pre ted ac cor ding to the cli ni cal context. 26 In ova ri an gro up, the antigen level in cre a sed mo re than twenty ti mes. In our study, both se rum and as ci tic flu id CA-125 va lu es in ova ri an can cer gro up were very high. Ho we ver, par ti cu larly as cites flu id CA-125 va lu e was hig her than all the other gro ups with sta tis ti cal sig ni fi can ce.
CA-125 le vels may ri se in a wi de va ri ety of non-ma lig nant di se a ses, and es pe ci ally in ef fu si ons and in fec ti ons. Ele va ted se rum CA-125 le vels were de tec ted in 100% of pa ti ents with nong yne co logic pe ri to neal car ci no ma to sis. 12 In the ir study, Ke mer et al. de ter mi ned that se rum CA-125 va lues in can cer gro up we re lo wer when compared to be nign gro up, however, as ci tic flu id CA-125 va lues we re hig her than the be nign gro up. 5 In our study, both se rum and as ci tic flu id le vels in nonova ri an ma lig nancy gro up we re hig her than be nign disorders, and the re was a sta tis ti cal sig ni fi can ce in as ci tic flu id CA-125 le vel.
With res pect to the me an va lu e of CA-125 levels, our results we re high in all gro ups in ves ti gated. In be nign gro up, we fo und me an se rum va lu es 14 and me an as ci tic flu id va lu es 19 ti mes hig her when compared to CA-125 cut-off le vels pro posed by ma nu fac tu red com pany. In non-ova ri an ma lig nancy gro up and ova ri an gro up, the an ti gen was increased mo re than twenty ti mes. Ac cor ding to se rum le vels of CA-125, the re we re no sig ni ficant dif fe ren ces bet we en the two gro ups. In contrary, as ci tic flu id le vels of CA-125 in ma lig nant group we re sig ni fi cantly hig her than be nign group. This in cre a se was es pe ci ally re mar kab le in ova ri an car ci no ma. Ac cor ding to the out co mes of the cur rent study, whilst me an va lu es of as ci tic flu id CA-125 in non-ova ri an and ova ri an can cers we re fo und abo ve 1000 U/ml, in be nign pa ti ents, it was 684 U/ml. In ad di ti on, among a to tal of 119 pa ti ents with as ci tic flu id CA-125 le vels abo ve 1000 U/mL, 51% was di ag no sed with non-ova ri an ma lig nan ci es and 25% with ova ri an car ci no ma.
In conc lu si ve re sults from the ro u ti ne analy sis of as ci tes co uld le ad to a de ci si on to perform a mo -re in va si ve di ag nos tic investigation, such as la paros copy etc. It wo uld be help ful to ha ve new pa rame ters to spe ed up the di ag nos tic pro cess. To our best know led ge, the re is no da ta fo cu sed on the cut-off va lu e of as ci tic flu id CA-125. In the pre sent study, the re we re dif fe ren ces, in terms of as citic flu id CA-125 however the dis cri mi na ti ve abi lity of this mar ker for non-ova ri an ma lig nancy, ova ri an can cers and be nign gro up was not ef fi cient. Thus, we co uld not find an ac cep tab le cut-off va lu e for as ci tic flu id CA-125 to distinguish between ova ri an, non-ova ri an ma lig nant pa ti ents and be nign disorders. The dis cri mi na ti ve abi lity of asci tic flu id CA-125 was po or, and this fin ding supports the study of Ke mer et al. 5 Ho we ver, we can spe cu la te that a CA-125 le vel over 1000 U/ml may indicate the need for an in va si ve di ag nos tic app lica ti on such as la pa ros copy.
In conc lu si on, our fin dings sup port the opi nion that CA-125 is not a spe ci fic tu mor mar ker for ova ri an car ci no ma, but the le vels over 1000 U/ml may be as so ci a ted with ova ri an or non-ova ri an malig nan ci es. The re fo re, we re com mend stud ying CA-125 in as ci tic flu id in a pa ti ent pre sen ted with as ci tes du e to the fact that CA-125 is produced by me sot he li al cells.
